Many Women Have Preexisting Modifiable Risk Factors for Birth Defects
By Elana Gotkine HealthDay Reporter

TUESDAY, Aug. 26, 2025 -- About two-thirds of reproductive-aged women in the United States have preexisting modifiable risk factors for birth defects, according to a study published online Aug. 26 in the American Journal of Preventive Medicine.
Arick Wang, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues used cross-sectional data from the National Health and Nutrition Examination Survey 2007 to March 2020 to examine the prevalence and trends of risk factors for selected birth defects among nonpregnant, nonlactating women of reproductive age (aged 12 to 49 years).
The researchers found that about 66.4 percent of 5,374 women of reproductive age had at least one known modifiable risk factor: 6.7, 33.8, 4.8, 18.8, and 19.5 percent reported very low food security, obesity, diabetes, smoking exposure, and red blood cell folate concentration below the threshold for optimal neural tube defect prevention. The percentage of women of reproductive age with at least one risk factor increased from 65.3 to 69.5 percent during the time studied.
"Every growing family hopes for a healthy pregnancy and healthy baby," Wang said in a statement. "Understanding modifiable risk factors for birth defects helps families, health care providers, and public health professionals make data-informed decisions that can lead to healthier pregnancies and babies."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-27 06:00
Read more

- Bird Flu May Spread Through Air, Wastewater on Dairy Farms
- Rate of Sexual Dysfunction Similar in Middle-Aged, Older Women
- Drug Overdoses in Health Care Workers Often Involve Drugs Obtained From Workplace
- FDA Approves Ajovy for Migraine Prevention in Children and Teens
- Florida Officials Warn About Raw Milk After 21 People Are Sickened
- FDA Approves Skytrofa (lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions